Hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, PMMA. Juvéderm, Restylane, RHA, Belotero, Sculptra, Radiesse, Bellafill.
A regulatory and clinical profile analyzing Prollenium's Revanesse filler line, its single FDA PMA P160042 architecture, Thixofix cross-linking, and MAUDE safety data.
A regulatory and clinical profile analyzing Teoxane's RHA Collection, its single FDA PMA P170002 architecture, Preserved Network Technology, and post-market safety data.
An evidence-based guide to hyperdiluted Radiesse (calcium hydroxylapatite) for skin tightening and body biostimulation, detailing dilution protocols, FDA PMA status, and…
A review of the newest FDA dermal filler approvals (Evolysse, saypha MagIQ, Belotero Volume) under product code LMH. Compares chemistry, cross-linking technology, PMA…
A clinical, evidence-first comparison of the only two FDA-approved dermal fillers for hand rejuvenation, reviewing chemical mechanisms, pivotal trials, and safety…
An evidence-based pre-treatment guide on blood thinners and supplements for Botox and fillers, analyzing bruising mechanisms, prescription protocols, and technique…
FDA warnings on needle-free dermal filler devices (Hyaluron Pens). High-pressure jet injection carries severe risks of skin necrosis, permanent blindness, and clinical…
Bellafill is the only FDA-approved permanent dermal filler in the US — PMMA microspheres that stay for years. What it is approved for, who is not a candidate, and why it…
22,242 FDA MAUDE reports for dermal fillers (product code LMH): the Juvéderm family leads at 55%, HA fillers drive 72% of all reports, and a 2025 surge pushed annual…
Sculptra (PLLA) can cause firm nodules months after injection that cannot be dissolved like HA filler. What the FDA trial and clinical literature say about incidence,…